Recent Updates
Recently added Catalysts
NBIX Positive Sentiment

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Key Takeaway: Neurocrine Biosciences has announced a conference call and webcast to discuss its second quarter 2026 financial results. Scheduled for July 30, 2026, the call will begin at 1:30 p.m. PT. The company aims to provide updates on its financial performance and ongoing projects, showcasing its commitment to addressing neurological and psychiatric disorders.
Price reaction · baseline $180.55 (2026-07-09 close) · hit after-hours · clean, no other NBIX news in the window
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Neurocrine Biosciences is actively engaging with investors.
  • The company has a diverse portfolio of FDA-approved treatments.
  • The upcoming conference call will provide insights into financial results.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
3.5%
average across 4 past catalysts
Lead asset
NBI-6024
Phase 1 · Type 1 Diabetes Mellitus

Full Press Release Details

Conference Call and Webcast Scheduled for Thursday, July 30

SAN DIEGO,July 9, 2026/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026.
The schedule for the press release and conference call / webcast is as follows:
• Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
• Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-347-6865
• International Dial-In Number: 203-518-9757
• Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors atwww.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine BiosciencesNeurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visitneurocrine.com, and follow the company onLinkedIn,X,FacebookandYouTube. (*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

Frequently Asked Questions

When is the Neurocrine Q2 2026 conference call?

The conference call is scheduled for July 30, 2026, at 1:30 p.m. PT.

How can I access the Neurocrine webcast?

The webcast can be accessed on Neurocrine Biosciences' website under the Investors section.

What is the purpose of the conference call?

The call will discuss Neurocrine's financial results for the second quarter of 2026.

Will there be a replay of the conference call?

Yes, a replay will be available on the website approximately one hour after the event.

Last updated: Jul 9, 2026